SCHEMBL1206172

SCHEMBL1206172

CCCN(CCC)CCCNC(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.60
DRD2 P14416 3/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
GAA P10253 1/20 0.53
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
CA12 O43570 5/20 0.47
CA1 P00915 5/20 0.47
CA14 Q9ULX7 2/20 0.47
CA7 P43166 1/20 0.47
CA2 P00918 4/20 0.47
CA9 Q16790 4/20 0.47
ACHE P22303 2/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
EPHX1 P07099 2/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1206871 0.94 TDP1 (0.61) TDP1DRD2MEN1KMT2AGAA
SCHEMBL17190611 0.93 TDP1 (0.60) TDP1DRD2MEN1KMT2AGAA
SCHEMBL15610483 0.93 TDP1 (0.68) TDP1DRD2MEN1KMT2AGAA
SCHEMBL25956633 0.93 TDP1 (0.53) TDP1DRD2MEN1KMT2AGAA
SCHEMBL24849943 0.90 TDP1 (0.61) TDP1DRD2MEN1KMT2AGAA
SCHEMBL11346435 0.90 CA12 (0.50) TDP1DRD2MEN1KMT2AGAA
SCHEMBL16558069 0.90 TDP1 (0.53) TDP1DRD2MEN1KMT2AGAA
SCHEMBL28425597 0.88 TDP1 (0.62) TDP1DRD2MEN1KMT2AGAA
SCHEMBL19123153 0.88 TDP1 (0.67) TDP1DRD2MEN1KMT2AGAA
SCHEMBL9773831 0.88 TDP1 (0.67) TDP1DRD2MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 US disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 TDP1 4143/4885DRD2 354/4885MEN1 1206/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 TDP1 4336/4885DRD2 263/4885MEN1 721/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 TDP1 4598/4885DRD2 433/4885MEN1 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.